John Santini

John Santini has held a number of executive roles in the biotechnology industry since 1999. John began their career as the President & CEO and Chief Scientific Officer of MicroCHIPS, Inc., a company they co-founded. From 2010 to 2012, they served as President & CEO of On Demand Therapeutics, Inc. and from 2012 to 2014 as President & CEO of RadioRx, Inc. (now EpicentRx). In 2014, they became the Chief Technology Officer of IRISense, LLC. In 2013, they co-founded ApoGen Biotechnologies, Inc., where they served as a Board Member. Since 2016, they have been the President & CEO of Vergent Bioscience, Inc., a company developing an injectable, tumor-targeted imaging probe.

John Santini attended Hanover Horton High School before pursuing a BSE in Chemical Engineering at the University of Michigan from 1990 to 1994. John then went on to receive their PhD in Chemical Engineering from the Massachusetts Institute of Technology in 1999.